We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Keytruda & Gardasil Aid Merck (MRK) Sales in Q4 Earnings?
Read MoreHide Full Article
Merck (MRK - Free Report) boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales. Keytruda has played an instrumental role in driving Merck’s steady revenue growth in the past few years.
Keytruda is already approved for the treatment of many cancers globally. Keytruda sales in the fourth quarter are likely to have been driven by continued strong momentum in metastatic indications, including in some types of NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma, TNBC and MSI-H cancers and rapid uptake across recent earlier-stage launches. The Zacks Consensus Estimate for Keytruda’s sales is $5.57 billion, while our estimate is $5.62 billion.
Merck’s stock has risen 31.8% in the past year compared with an increase of 9.1% for the industry.
Image Source: Zacks Investment Research
In the United States, Keytruda is expected to show strong growth across all types of cancers, including uptake from launches in earlier-stage cancers, including triple-negative breast, renal cell carcinoma and melanoma. Keytruda is presently approved to treat six indications in earlier-stage cancers in the United States.
In outside U.S. market, growth is likely to have been driven by lung cancer indications and head and neck cancer and renal cell carcinoma. Last quarter, Merck said it is witnessing a strong start to recently approved earlier stage indications. It remains to be seen how sales in early-stage cancers picked up in the fourth quarter.
Merck’s HPV vaccine, Gardasil, is expected to be another key top-line driver in the fourth quarter. Gardasil’s ex-U.S. sales are expected to have been driven by strong demand in China and increased supply in the fourth quarter. The favorable timing of CDC purchasing, which benefited U.S. sales in the third quarter, is likely to have reversed in the fourth quarter. The Zacks Consensus Estimate for Gardasil is $1.5 billion, while our estimate is $1.45 billion.
Overall, strong global underlying demand across its business, particularly for Keytruda and Gardasil, is likely to have boosted sales growth in the fourth quarter like several previous quarters.
Estimates for Sanofi’s 2023 earnings per share have increased from $4.25 per share to $4.41 in the past 60 days. Sanofi’s stock has declined 5.4% in the past year.
Sanofi beat earnings expectations in all the trailing four quarters. The company delivered a four-quarter earnings surprise of 9.50%, on average. Sanofi is scheduled to report fourth-quarter results on Feb 3.
Estimates for Roche’s 2023 earnings per share have jumped from $2.79 per share to $2.85 in the past 60 days. Roche’s stock has declined 19.4% in the past year.
Roche is scheduled to report fourth-quarter results on Feb 2.
Novo Nordisk’s earnings estimates for 2023 have increased from $4.00 per share to $4.18 in the past 60 days. Novo Nordisk’s stock has risen 39% in the past year.
Novo Nordisk beat earnings expectations in three of the trailing four quarters. The company delivered a four-quarter earnings surprise of 3.09%, on average. Novo Nordisk will report fourth-quarter results before market open on Feb 1.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Will Keytruda & Gardasil Aid Merck (MRK) Sales in Q4 Earnings?
Merck (MRK - Free Report) boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales. Keytruda has played an instrumental role in driving Merck’s steady revenue growth in the past few years.
Keytruda is already approved for the treatment of many cancers globally. Keytruda sales in the fourth quarter are likely to have been driven by continued strong momentum in metastatic indications, including in some types of NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma, TNBC and MSI-H cancers and rapid uptake across recent earlier-stage launches. The Zacks Consensus Estimate for Keytruda’s sales is $5.57 billion, while our estimate is $5.62 billion.
Merck’s stock has risen 31.8% in the past year compared with an increase of 9.1% for the industry.
Image Source: Zacks Investment Research
In the United States, Keytruda is expected to show strong growth across all types of cancers, including uptake from launches in earlier-stage cancers, including triple-negative breast, renal cell carcinoma and melanoma. Keytruda is presently approved to treat six indications in earlier-stage cancers in the United States.
In outside U.S. market, growth is likely to have been driven by lung cancer indications and head and neck cancer and renal cell carcinoma. Last quarter, Merck said it is witnessing a strong start to recently approved earlier stage indications. It remains to be seen how sales in early-stage cancers picked up in the fourth quarter.
Merck’s HPV vaccine, Gardasil, is expected to be another key top-line driver in the fourth quarter. Gardasil’s ex-U.S. sales are expected to have been driven by strong demand in China and increased supply in the fourth quarter. The favorable timing of CDC purchasing, which benefited U.S. sales in the third quarter, is likely to have reversed in the fourth quarter. The Zacks Consensus Estimate for Gardasil is $1.5 billion, while our estimate is $1.45 billion.
Overall, strong global underlying demand across its business, particularly for Keytruda and Gardasil, is likely to have boosted sales growth in the fourth quarter like several previous quarters.
Zacks Rank & Stocks to Consider
Merck has a Zacks Rank #3 (Hold) currently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merck & Co., Inc. Price and Consensus
Merck & Co., Inc. price-consensus-chart | Merck & Co., Inc. Quote
Some better-ranked large drugmakers are Sanofi (SNY - Free Report) , Roche (RHHBY - Free Report) and Novo Nordisk (NVO - Free Report) , all with a Zacks Rank #2 (Buy).
Estimates for Sanofi’s 2023 earnings per share have increased from $4.25 per share to $4.41 in the past 60 days. Sanofi’s stock has declined 5.4% in the past year.
Sanofi beat earnings expectations in all the trailing four quarters. The company delivered a four-quarter earnings surprise of 9.50%, on average. Sanofi is scheduled to report fourth-quarter results on Feb 3.
Estimates for Roche’s 2023 earnings per share have jumped from $2.79 per share to $2.85 in the past 60 days. Roche’s stock has declined 19.4% in the past year.
Roche is scheduled to report fourth-quarter results on Feb 2.
Novo Nordisk’s earnings estimates for 2023 have increased from $4.00 per share to $4.18 in the past 60 days. Novo Nordisk’s stock has risen 39% in the past year.
Novo Nordisk beat earnings expectations in three of the trailing four quarters. The company delivered a four-quarter earnings surprise of 3.09%, on average. Novo Nordisk will report fourth-quarter results before market open on Feb 1.